English  |  正體中文  |  简体中文  |  2809329  
???header.visitor??? :  26856617    ???header.onlineuser??? :  212
???header.sponsordeclaration???
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
???ui.leftmenu.abouttair???

???ui.leftmenu.bartitle???

???index.news???

???ui.leftmenu.copyrighttitle???

???ui.leftmenu.link???

"ren m"???jsp.browse.items-by-author.description???

???jsp.browse.items-by-author.back???
???jsp.browse.items-by-author.order1??? ???jsp.browse.items-by-author.order2???

Showing items 1-10 of 10  (1 Page(s) Totally)
1 
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2022-02-21T02:04:35Z Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT Okusaka T.; Ikeda K.; Kudo M.; Finn R.; Qin S.; Han K.-H.; ANN-LII CHENG; Piscaglia F.; Kobayashi M.; Sung M.; Chen M.; Wyrwicz L.; Yoon J.-H.; Ren Z.; Mody K.; Dutcus C.; Tamai T.; Ren M.; Hayato S.; Kumada H.
臺大學術典藏 2022-02-21T02:04:32Z Pharmacodynamic biomarkers predictive of survival benefit with lenvatinib in unresectable hepatocellular carcinoma: From the phase III REFLECT study Finn R.S.; Kudo M.; ANN-LII CHENG; Wyrwicz L.; Ngan R.K.C.; Blanc J.-F.; Baron A.D.; Vogel A.; Ikeda M.; Piscaglia F.; Han K.-H.; Qin S.; Minoshima Y.; Kanekiyo M.; Ren M.; Dairiki R.; Tamai T.; Dutcus C.E.; Ikezawa H.; Funahashi Y.; Evans T.R.J.
臺大學術典藏 2021-08-31T06:29:30Z Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial Kudo M.; Finn R.S.; Qin S.; Han K.-H.; Ikeda K.; Piscaglia F.; Baron A.; Park J.-W.; Han G.; Jassem J.; Blanc J.F.; Vogel A.; Komov D.; Evans T.R.J.; Lopez C.; Dutcus C.; Guo M.; Saito K.; Kraljevic S.; Tamai T.; Ren M.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:29:23Z Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma Evans T.R.J.; Kudo M.; Finn R.S.; Han K.-H.; ANN-LII CHENG; Ikeda M.; Kraljevic S.; Ren M.; Dutcus C.E.; Piscaglia F.; Sung M.W.
臺大學術典藏 2021-08-31T06:29:22Z Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6) Evans T.R.J.; Kudo M.; Finn R.S.; Han K.-H.; ANN-LII CHENG; Ikeda M.; Kraljevic S.; Ren M.; Dutcus C.E.; Piscaglia F.; Sung M.W.
臺大學術典藏 2021-08-31T06:29:20Z Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma Alsina A.; Kudo M.; Vogel A.; ANN-LII CHENG; Tak W.Y.; Ryoo B.-Y.; Evans T.R.J.; L?pez L?pez C.; Daniele B.; Misir S.; Ren M.; Izumi N.; Qin S.; Finn R.S.
臺大學術典藏 2019-07-11T03:52:26Z Medium optimization for enhanced lipid production by chlorella protothecoides UTEX25 Ogden K.;Ren M.;Cheng K.-C.; Cheng K.-C.; Ren M.; Ogden K.
臺大學術典藏 2019-07-11T03:52:26Z Medium optimization for enhanced lipid production by chlorella protothecoides UTEX25 Ogden K.;Ren M.;Cheng K.-C.; Cheng K.-C.; Ren M.; Ogden K.
臺大學術典藏 2019-07-11T03:52:26Z Medium optimization for enhanced lipid production by Chlorella protothecoides UTEX25 Ren M.; Ogden K.; Cheng K.-C.; Ogden K.;Ren M.;Cheng K.-C.
臺大學術典藏 2019-07-11T03:52:26Z Medium optimization for enhanced lipid production by Chlorella protothecoides UTEX25 Ren M.; Ogden K.; Cheng K.-C.; Ogden K.;Ren M.;Cheng K.-C.

Showing items 1-10 of 10  (1 Page(s) Totally)
1 
View [10|25|50] records per page